



Intellia Therapeutics to Present at September Investor Healthcare Conferences

September 1, 2016

CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessian Bermingham, Ph.D., will present at key September investor healthcare conferences, including the 2016 Wells Fargo Healthcare Conference, the Morgan Stanley Global Healthcare Conference and the Leerink Rare Disease & IO Roundtable Series.

Details of the upcoming presentations are as follows:

Wednesday, September 7th

2016 Wells Fargo Healthcare Conference

Location: The Westin Waterfront, Boston

Presentation Time: 3:30-4:00 PM ET

Tuesday, September 13th

2016 Morgan Stanley Global Healthcare Conference

Location: Grand Hyatt New York, New York

Presentation Time: 5:15-5:40 PM ET

Wednesday, September 28th

Leerink Rare Disease & IO Roundtable Series, 2016

Location: Lotte New York Palace, New York

Presentation Time: 2:05-2:30 PM ET

Individuals may access the presentations for each conference via live webcast on the Intellia website at www.intelliatrix.com under "Events & Presentations" in the "Investor Relations" section. A replay of the webcast will be available on this site for 90 days following the live event.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatrix.com; Follow us on Twitter @intellitweets.

Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
jenn.smoter@intelliatrix.com

Investor Contacts:

John Graziano
Trout Group
+1 646-378-2942
jgraziano@troutgroup.com

Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com



Intellia Therapeutics, Inc.